LarryLKestinMDFACR, FASTRO
Radiation Oncology • Farmington Hills, MIGastrointestinal Cancer, Sarcoma, Thoracic Cancer, Urologic Cancer
Medical Director, MHP Radiation Oncology Institute; Clinical Professor, Wayne State University
Dr. Kestin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
28595 Orchard Lake Rd
Suite 110
Farmington Hills, MI 48334Phone+1 248-553-0606Fax+1 248-553-7674
Summary
- Larry L. Kestin, MD, FACR, FASTRO has authored over 400 peer-reviewed journal publications, abstracts and book chapters. He is a radiation oncology written and oral boards examiner for the American Board of Radiology and Chair of the Lung/Sarcoma section. He is a member of the NCI Thoracic Malignancy Steering Committee and has been a member of multiple ASTRO Committees. He has held academic appointments as a full professor at Oakland University and UCLA and was Program Director for the Department of Radiation Oncology at William Beaumont Hospital. Dr. Kestin is also a Clinical Professor at Wayne State University. He is actively involved in clinical research and has served as Principal Investigator for many local as well as national clinical trials
Education & Training
Corewell Health East Beaumont (Royal Oak)Residency, Radiation Oncology, 1995 - 2000
University of Kansas School of MedicineClass of 1995
University of Missouri-ColumbiaBS, Computer Science, 1986 - 1991
Certifications & Licensure
MI State Medical License 1997 - 2025- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Top Docs Hour Detroit Magazine, 2012, 2017-2024
- Best Doctors in America Best Doctors, 2005-2020
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012, 2014
- Join now to see all
Clinical Trials
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Start of enrollment: 2020 Apr 29
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Start of enrollment: 2019 Jun 03
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
- Join now to see all
Publications & Presentations
PubMed
- ACROPath Oligometastases: The American College of Radiation Oncology Clinical Pathway.Christopher D Jahraus, Paul E Wallner, Dwight E Heron, William Crook, Steven E Finkelstein
Cureus. 2024-11-01 - Factors associated with acute esophagitis during radiation therapy for lung cancer.Daniel J Herr, Huiying Yin, Derek Bergsma, Aleksandar F Dragovic, Martha Matuszak
Radiotherapy and Oncology. 2024-08-01 - Predictors of Early Hospice or Death in Patients With Inoperable Lung Cancer Treated With Curative Intent.Siddharth Ramanathan, Kimberly A Hochstedler, Anna M Laucis, Benjamin Movsas, Craig W Stevens
Clinical Lung Cancer. 2024-06-01
Press Mentions
Optimizing Nutritional Support in the Critically Ill: Evaluation of a Dedicated Team Approach to Placement of Nasojejunal Feeding TubesAugust 28th, 2024
Dr. Larry Kestin, 21st Century Oncology's Medical Director, Michigan Region, Named A Fellow of the American Society for Radiation and Oncology (ASTRO)October 2nd, 2019
Professional Memberships
- Fellow
- Fellow
- Member
- American College of Radiation Oncology - ACROMember
- American Radium Society - ARSMember
External Links
- MHP Radiation Oncology Institutehttps://www.mhpdoctor.com/radiation-centers
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
